Lance Berry Sells 4,485 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) EVP Lance Berry sold 4,485 shares of Artivion stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $35.69, for a total value of $160,069.65. Following the transaction, the executive vice president owned 143,965 shares of the company’s stock, valued at $5,138,110.85. This represents a 3.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Artivion Stock Up 6.6%

AORT opened at $38.14 on Friday. The stock’s fifty day simple moving average is $42.09 and its 200 day simple moving average is $43.05. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25. The stock has a market cap of $1.83 billion, a PE ratio of 190.71 and a beta of 1.59. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The firm had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The firm’s revenue for the quarter was up 19.2% on a year-over-year basis. As a group, research analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Key Headlines Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 results topped expectations — revenue grew ~19% year‑over‑year and EPS beat consensus, supporting revenue momentum and margin recovery; this helps justify the current rally. Earnings & Company Page
• Positive Sentiment: Short interest fell ~15.4% in February to ~1.39M shares (~3.2% of float); lower short exposure reduces one source of downside selling and can make up‑moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Institutional investors have increased or initiated positions in recent quarters (multiple funds cited), indicating professional conviction that could support longer‑term demand. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed — consensus is a “Moderate Buy” with an average target near $49, but some shops have trimmed targets or moved to Hold, reflecting divergent views on near‑term upside. Analyst Notes
• Negative Sentiment: Large, broad insider selling across Feb. 23–24 (CEO James P. Mackin, EVP Lance Berry, SVPs and CAO made sizable open‑market disposals). While filings suggest open‑market liquidity/scheduled sales rather than insider panic, the scale and breadth can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Hedge Funds Weigh In On Artivion

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kennedy Capital Management LLC lifted its position in shares of Artivion by 20.8% during the 2nd quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock valued at $11,437,000 after acquiring an additional 63,205 shares during the period. Squarepoint Ops LLC acquired a new position in Artivion in the second quarter valued at about $664,000. Oppenheimer Asset Management Inc. acquired a new position in Artivion in the second quarter valued at about $669,000. Sio Capital Management LLC lifted its position in Artivion by 31.0% during the second quarter. Sio Capital Management LLC now owns 158,736 shares of the company’s stock worth $4,937,000 after purchasing an additional 37,558 shares during the period. Finally, Atria Investments Inc acquired a new stake in Artivion during the second quarter worth about $244,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Needham & Company LLC reissued a “buy” rating and set a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Citizens Jmp upped their price objective on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Canaccord Genuity Group lowered their price objective on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Finally, Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $48.97.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.